Abstract
Immunotherapy strategies targeting the programmed cell death ligand 1 (PD-L1)/programmed cell death 1 (PD-1) pathway in clinical treatments have achieved remarkable success in treating multiple types of cancer. However, owing to the heterogeneity of tumors and individual immune systems, PD-L1/PD-1 blockade still shows slow response rates in controlling malignancies in many patients. Accumulating evidence has shown that an effective response to anti-PD-L1/anti-PD-1 therapy requires establishing an integrated immune cycle. Damage in any step of the immune cycle is one of the most important causes of immunotherapy failure. Impairments in the immune cycle can be restored by epigenetic modification, including reprogramming the environment of tumor-associated immunity, eliciting an immune response by increasing the presentation of tumor antigens, and by regulating T cell trafficking and reactivation. Thus, a rational combination of PD-L1/PD-1 blockade and epigenetic agents may offer great potential to retrain the immune system and to improve clinical outcomes of checkpoint blockade therapy.
Citations
Aug 5, 2020·Journal of Gastroenterology·Fiona TurkesNaureen Starling
Oct 9, 2020·International Journal of Molecular Sciences·Haiyan DaiJie Ma
Oct 20, 2020·Frontiers in Oncology·Chaoyue SuJianye Zhang
Nov 11, 2020·Biomaterials Science·Bin TuYongzhuo Huang
Nov 25, 2020·Journal of Experimental & Clinical Cancer Research : CR·Yuanliang YanZhijie Xu
Dec 17, 2020·Cancers·Laura BoyeroReyes Bernabé-Caro
Oct 23, 2020·Vaccines·Caterina LapentaStefano Maria Santini
Nov 12, 2020·International Journal of Molecular Sciences·Simone PatergnaniCarlotta Giorgi
Jan 6, 2021·Cancers·Ana S LealKaren T Liby
Mar 2, 2021·Acta Pharmaceutica Sinica. B·Jianfeng WangYiran Huang
Mar 18, 2021·Medicine·Jingyan XuBing Chen
Mar 26, 2021·Clinical Epigenetics·Iris LodewijkJesús M Paramio
Mar 26, 2021·International Immunopharmacology·Xiaoxu Li, Wenling Zhang
Mar 9, 2021·Signal Transduction and Targeted Therapy·Chaoyue SuLiwu Fu
Mar 30, 2021·Acta Pharmaceutica Sinica. B·Jinghui ZhangKai Yin
Jan 19, 2021·Aging·Zhiwei ZhaoZhenan Zhang
Apr 11, 2021·Cancer Letters·Sepideh MirzaeiGautam Sethi
Jun 23, 2021·Journal of Experimental & Clinical Cancer Research : CR·Jingtong ZhangXu Chen
Dec 21, 2021·Frontiers in Cell and Developmental Biology·Fangdie YeHaowen Jiang
Jan 20, 2022·Journal of Medicinal Chemistry·Xiaopeng PengJianjun Chen